Source comparison
Comparison Table: MK-677 Long-Term Effects by Duration
This table summarises the timeline and severity of metabolic and physiological changes observed in clinical trials of varying durations. Fasting Glucose Elevation Minimal (1–3 mg/dL) Moderate (6–10 mg/dL) Significant (8–15 mg/dL) 4–8 weeks post-cessation Dose-
This comparison does not assign a generated winner or score.
- This table summarises the timeline and severity of metabolic and physiological changes observed in clinical trials of varying durations.
- Fasting Glucose Elevation
- Minimal (1–3 mg/dL)
- Moderate (6–10 mg/dL)
- Significant (8–15 mg/dL)
- 4–8 weeks post-cessation
- Dose-dependent; higher risk in individuals with baseline HbA1c >5.7% or metabolic syndrome
- Insulin Resistance
- Not detectable
- Measurable (HOMA-IR ↑20–30%)
- Pronounced (HOMA-IR ↑30–50%)
- 6–10 weeks post-cessation
- Functional adaptation, not beta-cell damage. Returns to baseline in healthy individuals
- Cortisol Elevation
- Transient spike
- Sustained ↑20–30%
- Sustained ↑30–40%
- 2–4 weeks post-cessation
- Exacerbates stress-related symptoms; avoid in individuals with pre-existing HPA dysregulation
- Edema/Water Retention
- Mild, transient
- Persistent in 15–25%
- Persistent in 25–40%
- 8–12 weeks post-cessation
- Carpal tunnel risk increases beyond six months; sodium restriction may mitigate
- Appetite Stimulation
- Strong (ghrelin mimicry)
- Moderate (tolerance develops)
- Variable (individual)
- Immediate upon cessation
- Caloric surplus risk. Track intake to prevent unintended weight gain